• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

J&J’s IL-23 star guselkum­ab grabs the spot­light in PhI­II pso­ri­a­sis show­down

9 years ago
R&D

Block­buster per­for­mance: Re­gen­eron, Sanofi add stel­lar PhI­II dupilum­ab da­ta on dis­play at EADV

9 years ago
R&D

Fol­low­ing lethal tox re­port, Boehringer scraps plans for high-speed de­vel­op­ment, kills $730M Han­mi deal

9 years ago
R&D

Thresh­old blast­ed, re­struc­tures af­ter a PhII fail­ure; SQZ rais­es $16M

9 years ago
News Briefing

Week in re­view: Clin­ton over Trump; the hubs have it; we'll al­ways have Paris

9 years ago
Bioregnum
Opinion

Scoop: Cel­gene tar­gets a cure for myelo­ma/lym­phoma with $600M En­gMab buy­out

9 years ago
Deals

In a set­back, Re­gen­eron re­ports a mid-stage flop for next-gen Eylea com­bo

9 years ago
R&D

Im­muno­Gen's new CEO re­trench­es, ax­ing 65 staffers and look­ing to thin pipeline

9 years ago
R&D
Pharma

UCSF sci­en­tist rolls out a new blue­print for pro­gram­ming T cells, the 2.0 way

9 years ago
Startups

Cataba­sis shares rock­et up on Duchenne pact with Sarep­ta; blue­bird whis­tles up a TCR deal with Medi­gene

9 years ago
News Briefing

Am­gen beefs up car­dio pipeline, adding a $673M RNAi deal with Ar­row­head

9 years ago
R&D

Step two: Cel­gene grabs a $20M op­tion, plots MS PhII for Abide’s cannabi­noid drug

9 years ago
R&D

No­vo Nordisk takes out the ax and aims at R&D, chop­ping 1,000 jobs

9 years ago
R&D
Pharma

Genen­tech snares a PhI RAF in­hibitor from Han­mi in $910M deal

9 years ago
R&D
Pharma

FDA slaps a full clin­i­cal hold on Al­co­bra’s trou­bled lead drug for AD­HD, Frag­ile X

9 years ago
R&D

No­var­tis, Am­gen rack up their first PhI­II suc­cess in a crowd­ed CGRP mi­graine drug field

9 years ago
R&D

The 2nd PhI­II schiz­o­phre­nia study for In­tra-Cel­lu­lar drug is a dis­as­ter, shares shred­ded

9 years ago
R&D

J&J hands Tra­con two drugs, out­lines buy­back; Zymeworks does a cross-li­cens­ing deal with Dai­ichi Sankyo

9 years ago
News Briefing

In­cyte’s IDO1 up­date on its Keytru­da com­bo scores some pos­i­tive re­views

9 years ago
R&D

Hub ap­peal: As­traZeneca is mar­shal­ing 350-plus R&D troops in new South San Fran­cis­co cam­pus

9 years ago
R&D
Pharma

Gear­ing up new part­ner­ships, Boehringer gets an op­tion to buy a new play­er in on­colyt­ic virus­es in $230M deal

9 years ago
R&D

GSK finds a buy­er will­ing to take its Paris R&D site off its hands — for a hefty fee

9 years ago
Pharma

Pi­lot crash crush­es lit­tle Galectin’s share price af­ter NASH study fails

9 years ago
R&D

No­var­tis vet O'­Dowd takes the helm at Neon; FDA slaps a hold on Cel-Sci's PhI­II can­cer study

9 years ago
News Briefing
First page Previous page 1154115511561157115811591160 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.